Treatment of solid tumors using antiangiogenic therapy has been explored for several decades.1,2 Discovery of vascular endothelial growth factor A (VEGF-A) as a major culprit in tumor angiogenesis led to the development of bevacizumab, a recombinant humanized monoclonal antibody targeting VEGF-A.3 Addition of bevacizumab to various chemotherapy regimens has proven highly beneficial in patients with several types of advanced solid tumors resulting in a significant improvement in overall survival (OS) and/or progression-free survival (PFS). This evidence concerns the gene VEGFA and neoplasm.